tenofovir disoproxil fumarate / Generic mfg. - LARVOL DELTA

Refractory Pruritus and Eosinophilic Dermatitis as the Sole Presenting Manifestation of Hepatocellular Carcinoma Arising From Occult Hepatitis B Infection (ACG 2026) - "The symptoms were unresponsive despite dermatological treatment with topical steroids, antihistamines, ivermectin, fluconazole, and doxycycline...He was started on dual immunotherapy with tremelimumab and durvalumab. Tenofovir disoproxil fumarate was initiated for HBV prophylaxis prior to immunotherapy...This case also highlights the importance of evaluating occult HBV infection in anti-HBc-positive patients and adds to emerging evidence supporting consideration of occult hepatitis B infection in future HCC surveillance guidelines. Figure: Figure 1: Eroded crusted erythematous papules on erythematous base in anterior chest and erythematous pink lichenified papules coalescing into plaques in lower abdomen Figure: Figure 2: Triple phase CT abdomen and pelvis demonstrating a large hepatic mass (20.1 Ã 12.6 Ã 14.8 cm) involving both left and right lobes with hypervascularity ( Image A: arterial phase ) and washout ( Image B: portal venous phase and Image C: delayed..."

Acute Lymphocytic Leukemia • Dermatitis • Dermatology • Hematological Malignancies • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Lymphoblastic Lymphoma • Lymphoma • Oncology • Pruritus • Skin Cancer • Solid Tumor • AFP

Insights from strengthening perinatal hepatitis b prevention in healthcare facilities in Delta State, Nigeria: A prospective, pilot implementation intervention. (PubMed, Sage Open Chronic Dis) - "HBV-positive women were linked to care and initiated on tenofovir disoproxil fumarate (TDF) prophylaxis...Project StopHepB interventions significantly improved early identification, linkage to care, and timely HepB-BD vaccination, effectively closing gaps in HBV prevention of perinatal transmission. These findings support the scale-up of similar interventions to advance HBV elimination goals across other facilities in the state, in Nigeria, and to prevent new HBV infections in the future."

Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Oncology

In utero and lactational exposure to tenofovir disoproxil fumarate and bone health outcomes: a scoping review of 31 studies. (PubMed, Front Endocrinol (Lausanne)) - "In utero and lactational exposure to TDF had minimal impact on paediatric bone development but was consistently linked to maternal bone loss and incomplete skeletal recovery. While the benefits of TDF in preventing vertical transmission of HIV and HBV outweigh these risks, the findings highlight the importance of ongoing monitoring of maternal bone health."

HEOR • Journal • Review • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Osteoporosis • Pediatrics • Rheumatology

Hepatitis B virus genome mutations in precore and basal core promoter regions among HBeAg-negative chronic hepatitis B patients with high viral load in Indonesia. (PubMed, PLoS One) - "Hepatitis B e antigen (HBeAg) is widely used as a marker for active HBV replication and serves as a surrogate for HBV DNA > 200,000 IU/mL to determine eligibility for tenofovir disoproxil fumarate (TDF) prophylaxis to prevent vertical transmission, according to WHO guidelines...These exploratory findings provide regional NGS-based molecular evidence that established PC mutations may contribute to the coexistence of HBeAg negativity and continued high-level HBV replication in Indonesian patients. Larger studies incorporating broader virological and clinical comparison groups are required to determine the clinical significance of these findings."

Journal • Hepatitis B • Infectious Disease • Inflammation

Biomphalaria glabrata as a possible experimental model for investigating anti-inflammatory substances. (PubMed, Biochem Biophys Rep) - "Substances such as hydrocortisone and Tenofovir Disoproxil Fumarate (TDF) have demonstrated the ability to alter immune responses in B. glabrata, either by suppressing hemocyte function, reducing oxidative stress, or regulating immune signaling pathways. Due to its low maintenance cost, ease of handling, and rapid life cycle, B. glabrata represents a valuable invertebrate model for early-stage screening of immunomodulatory and potentially therapeutic compounds. Overall, this work supports the use of B. glabrata as a viable alternative model in research, contributing to the development of novel anti-inflammatory strategies and reducing the need for early testing in mammalian systems."

Journal • Review • Infectious Disease • Inflammation

Long-Term Viral Suppression and Cardiometabolic Benefits of Switching to Ainuovirine/Lamivudine/Tenofovir DF in Virologically Suppressed People with HIV-1: 192-Week Extended Results from the SPRINT Study (IDWeek 2026) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Comparison of Peg-INF plus TDF versus TDF Monotherapy in Indeterminate-phase Chronic Hepatitis B Patients with High HBsAg levels, HBeAg-negative status, and Normal ALT Levels. (PubMed, J Clin Transl Hepatol) - "In this investigator-initiated, open-label clinical trial, we randomly assigned participants aged 18 to 60 years with HBeIP characteristics to receive either tenofovir disoproxil fumarate (TDF) monotherapy (monotherapy group) or pegylated interferon alfa-2b (Peg-IFNα-2b) plus TDF (combination group)...In contrast, only two participants (1.5%) in the monotherapy group achieved HBsAg <1,500 IU/mL. Compared with TDF monotherapy, combination therapy with Peg-IFNα-2b and TDF significantly improved both HBsAg <1,500 IU/mL and HBsAg loss rates in HBeIP patients."

Journal • Monotherapy • Hepatitis B • Infectious Disease • Inflammation • IFNA1

Renal function and urinary tubular biomarker abnormalities in untreated and entecavir- or tenofovir disoproxil fumarate-treated patients with chronic hepatitis B: a retrospective cross-sectional study. (PubMed, Front Med (Lausanne)) - "These findings represent cross-sectional associations rather than evidence of treatment-induced renal injury. The absence of pretreatment and serial renal measurements, urinary creatinine normalization, and a complete proximal tubular dysfunction assessment requires cautious interpretation and prospective longitudinal confirmation."

Biomarker • Journal • Observational data • Retrospective data • Hepatitis B • Infectious Disease • Inflammation • Renal Disease • B2M

Letter: Calendar Era or Antiviral Choice-What Explains the Survival Benefit of Tenofovir Disoproxil Fumarate After Hepatocellular Carcinoma Resection? Authors' Reply. (PubMed, Aliment Pharmacol Ther) - No abstract available

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Profile of People Living with HIV Switching Prior Antiretroviral Treatment to a Doravirine-Based Regimen in the Real-World Clinical Setting in Greece: The Retrospective DORAVITO Study. (PubMed, Biomedicines) - "Most PLWH (98.2%) were prescribed DOR plus two nucleoside reverse transcriptase inhibitors; 87.3% were prescribed DOR/Lamivudine/Tenofovir Disoproxil Fumarate fixed-dose combination. This study highlights the patterns of DOR use in real-life clinical practice in Greece among treatment-experienced PLWH. Physicians switch HIV-1-infected individuals from prior ART to DOR-based regimens to offer a simplified regimen or to avoid or prevent toxicity."

Journal • Real-world evidence • Retrospective data • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

On the Verge of the 3000th Publication: Reflections on Deceptions, Successes and Perspectives. (PubMed, Molecules) - "A lifelong career devoted to the development of specific antiviral agents eventually yielded, besides (almost) 3000 publications, about ten antiviral compounds that were approved and marketed as antiviral drugs, i.e., DHPA (Duviragel®), BVDU (Zostex®, Mevir®, Brivir®…), VACV (Zelitrex®, Valtrex®), d4T (Stavudine®), emivirine (Coactinon®), rilpivirine (Edurant®), HPMPC (Vistide®), PMEA (Hepsera®), tenofovir (Viread®) and AMD-3100 (Mozobil®), with the latter as a hematopoietic stem cell mobilizer. The targeted viruses for these compounds were herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), human immunodeficiency virus (HIV), and hepatitis B virus (HBV). For other viruses, such as filo-, rhabdo-, arena-, myxo-, polyoma- and papillomaviruses, strategies have been elaborated that should facilitate future developments of antiviral drugs."

Journal • Review • Cytomegalovirus Infection • Hepatitis B • Herpes Simplex • Herpes Zoster • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Oncology • Varicella Zoster

Never Too Late: A Case Report of Severe Fanconi Syndrome Developing After More than a Decade of Silent Tenofovir Disoproxil Fumarate Exposure. (PubMed, Reports (MDPI)) - "TDF was discontinued, and her antiretroviral regimen was modified to tenofovir alafenamide fumarate (TAF), emtricitabine (FTC), darunavir, and ritonavir, combined with vitamin D supplementation. Over a 6-month follow-up period, renal function normalized, electrolyte wasting resolved, and metabolic acidosis completely reversed. This case highlights that TDF-induced proximal tubulopathy can manifest even after a decade of uneventful therapy, particularly when co-administered with a boosted protease inhibitor."

Journal • Endocrine Disorders • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Pain • Renal Disease • Secondary Hyperparathyroidism

Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual, and other men who have sex with men in Spain. (PubMed, Lancet Reg Health Eur) - "Substantial price reductions will likely be required to enable equitable access and realise its full public health potential. None."

HEOR • Journal • Human Immunodeficiency Virus • Infectious Disease

A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) (clinicaltrials.gov) - P2 | N=200 | Active, not recruiting | Sponsor: Aligos Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatitis B • Infectious Disease • Inflammation

Bilateral Pathological Femoral Fractures Secondary to Long-Term Tenofovir Disoproxil Fumarate-Induced Osteomalacia in a Woman Living with HIV: A Case Report. (PubMed, Int Med Case Rep J) - "One year earlier, her regimen was switched to abacavir/lamivudine/dolutegravir due to emerging bone pain. Serum phosphate and alkaline phosphatase normalized, bone pain resolved, and no new fractures occurred, though full ambulation remained limited due to complications. This case demonstrates TDF as a reversible cause of severe osteomalacia and pathological fractures in long-term HIV treatment, emphasizing early recognition, regimen substitution to non-TDF agents, and proactive bone/mineral monitoring to prevent such outcomes in vulnerable populations."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Oncology • Orthopedics • Osteoporosis • Pain • Renal Disease

Letter: Calendar Era or Antiviral Choice-What Explains the Survival Benefit of Tenofovir Disoproxil Fumarate After Hepatocellular Carcinoma Resection? (PubMed, Aliment Pharmacol Ther) - No abstract available

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Rapid cross-sectional impact assessment of an earthquake on the continuity of antenatal care for pregnant women living with hepatitis B in Vanuatu. (PubMed, Dialogues Health) - "During routine monitoring calls, we asked additional questions about the impact of the earthquake on continued access to health services and continued use of daily hepatitis B antiviral prophylaxis with tenofovir disoproxil fumarate...In natural disaster-prone settings, it is critical that field research take an adaptive approach that can adjust and respond to health emergencies. While natural disasters are inevitable, health systems must implement risk mitigation strategies to limit interruptions to routine health services to reduce negative short-, medium-, and long-term health impacts of natural disasters."

Journal • Hepatitis B • Infectious Disease • Inflammation

Hepatitis B Reactivation After Kidney Transplantation in Hepatitis B Surface Antigen-Positive Recipients. (PubMed, Exp Clin Transplant) - "Although optimal duration of prophylactic antiviral therapy remains unclear, entecavir or tenofovir was the preferred antiviral therapy over lamivudine for hepatitis B virus reactivation prophylaxis. Close monitoring with antiviral prophylaxis is the optimal strategy to prevent hepatitis B virus reactivation during immunosuppressive therapy."

Biomarker • Journal • Retrospective data • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Failure • Transplantation

Association between integrase inhibitors (INSTIs) and tenofovir alafenamide (TAF) and moderate chronic kidney disease (CKD) in the RESPOND HIV cohort collaboration (AIDS 2026) - "We assessed CKD risks associated with (1) INSTIs vs non-nucleoside reverse transcriptase inhibitors (NNRTIs) and (2) TAF vs lamivudine (3TC), with both comparators considered kidney neutral...To account for artefactual creatinine increases when starting INSTIs and rilpivirine, baseline was defined as 6 months after starting treatment... After accounting for differences in participant characteristics, there was no increased CKD risk associated with INSTIs or TAF, although confidence intervals were relatively wide."

Cardiovascular • Chronic Kidney Disease • Diabetes • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • CD4

Antiretroviral treatment trajectories and post-listing outcomes in people living with HIV or AIDS listed for kidney or liver transplantation: a national cohort study in Brazil (AIDS 2026) - "Longer cumulative exposure to multiple antiretrovirals—including lamivudine, zidovudine, efavirenz, darunavir, dolutegravir, lopinavir, nevirapine, ritonavir, and tenofovir disoproxil fumarate—was consistently associated with lower post-listing mortality (Spearman ? In this nationwide study, longer cumulative exposure to widely used antiretrovirals was associated with lower mortality after listing, even for drugs traditionally described as hepatotoxic or nephrotoxic. This suggests, in this context, cumulative ART exposure primarily reflects sustained engagement in care, rather than a direct pharmacological toxicity effect on mortality. This first national linkage of transplant and HIV information systems provides evidence to inform the integration of HIV care and transplant services, and supports future evaluations of equity and outcomes among aging populations living with HIV."

Human Immunodeficiency Virus • Infectious Disease • Solid Organ Transplantation • Transplantation

A 48-week comparative analysis of metabolic outcomes in persons living with HIV on long-acting cabotegravir/rilpivirine versus oral antiretroviral therapy in the IMPALA trial (AIDS 2026) - "Although metabolic changes, such as weight gain, have been reported with dolutegravir (DTG) in African adults, evidence on metabolic effects of CAB is limited...540 participants on DTG-based ART (60% female, 49% aged 35–50) were randomized to switch to LAI CAB+RPV (n=271) or continue oral ART [n=269; 98.9% Tenofovir disoproxil fumarate (TDF)-based regimens]... Overall, these findings support the metabolic and renal safety of LAI CAB+RPV in African adults. While overall metabolic changes were minimal, females were at higher risk of clinically significant weight gain, underscoring the importance of sex-specific monitoring."

Chronic Kidney Disease • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Obesity

Prevention of HBV Mother-To-Child Transmission (MTCT) Using Targeted HBV Birth Dose, and Treatment of High Viral Load Pregnant Women in Uganda. (PubMed, J Viral Hepat) - "HVL mothers received Tenofovir Disoproxil Fumarate plus Lamivudine in the third trimester...Integrating maternal antiviral prophylaxis, targeted BD vaccination, and universal 3D vaccination achieved near-elimination of HBV MTCT in this setting. Nationally scaling this strategy could enable Uganda to meet the WHO target of less than 0.1% infant HBV prevalence before 2030 and serve as a model for other high-burden countries with significant rates of home births."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation

ELDORADO: DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-nave People Living With HIV-1 Infection (clinicaltrials.gov) - P3 | N=610 | Recruiting | Sponsor: ANRS, Emerging Infectious Diseases | Trial completion date: Nov 2027 ➔ Jan 2029 | Trial primary completion date: Nov 2026 ➔ Jan 2028

Head-to-Head • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CYP3A5

Open-label phase 1 study of the effects of emtricitabine/tenofovir disoproxil fumarate on the pharmacokinetics of MK-8527, a nucleoside reverse transcriptase translocation inhibitor, in adults without HIV (AIDS 2026) - P1 | "FTC/TDF administered 24 hours before MK-8527 led to a minor reduction in MK-8527-TP AUC 0-inf, but C trough levels at 4 weeks (672 hours) were similar. MK-8527 was generally well tolerated when given alone or following multiple daily doses of FTC/TDF. Table."

Clinical • P1 data • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • DCK

Long-term viral suppression, and cardiometabolic benefits of switch to ainuovirine coformulated with lamivudine, and tenofovir DF in virologically suppressed people with HIV-1: 144-week, open-label results from the SPRINT post-study (AIDS 2026) - "BACKGROUND: Previous 96-week results from the SPRINT extension study demonstrated that switching to the next-generation NNRTI ainuovirine coformulated with lamivudine and tenofovir DF (ANV/3TC/TDF) maintained viral suppression (VS) and improved cardiometabolic parameters in people with HIV-1 (PWH) switching from both classical NNRTI-based regimens and E/C/F/TAF. Switch to ANV/3TC/TDF maintained VS among PWH switching-off both classical NNRTIs-, and boosted INSTI-based regimens. The accompanied safety benefits included persistent improvement in LDL-C level, and ASCVD risk strata. Renal function remained stable among this population, and required general routine monitoring."

Clinical • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • CD4